Print Page      Close Window     

Press Release

Exelixis Announces Webcasts of Investor Conference Presentations in March

-- Presentations to be webcast on www.exelixis.com --

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar. 1, 2017-- Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide an overview of the company at the following two investor conferences in March:

  • Cowen Group 37th Annual Health Care Conference: Exelixis’ presentation is scheduled for 10:40 AM EST / 7:40 AM PST on Tuesday, March 7, 2017 in Boston.
  • Barclays Capital Global Healthcare Conference: Exelixis is scheduled to present at 2:05 PM EDT / 11:05 AM PDT on Tuesday, March 14, 2017 in Miami.

Each presentation will be webcast live and may be accessed via the Event Calendar page under Investors & Media at www.exelixis.com. Please connect to the company’s website at least 15 minutes prior to each presentation to ensure adequate time for any software download that may be required to listen to the webcast. Replays will also be available at the same location for 14 days following each presentation.

About Exelixis

Exelixis, Inc. (Nasdaq: EXEL) is a biopharmaceutical company committed to the discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. Since its founding in 1994, three products discovered at Exelixis have progressed through clinical development, received regulatory approval, and entered the marketplace. Two are derived from cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL and VEGF receptors: CABOMETYX™ tablets approved for previously treated advanced kidney cancer and COMETRIQ® capsules approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic®, is a formulation of cobimetinib, a selective inhibitor of MEK, is marketed under a collaboration with Genentech (a member of the Roche Group), and is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a variety of forms of cancer and are the subjects of broad clinical development programs. For more information on Exelixis, please visit www.exelixis.com or follow @ExelixisInc on Twitter.

Exelixis, the Exelixis logo, COMETRIQ and COTELLIC are registered U.S. trademarks, and CABOMETYX is a U.S. trademark.

Source: Exelixis, Inc.

Exelixis, Inc.
Susan Hubbard, 650-837-8194
Executive Vice President, Public Affairs and Investor Relations
shubbard@exelixis.com
or
Media Contact:
For Exelixis, Inc.
Hal Mackins, 415-994-0040
hal@torchcommunications.com